DermaEXO

Dementia diagnosis remains a significant challenge, as current methods are often invasive, costly, and unable to detect disease at an early stage. The DermaEXO project develops a novel, non-invasive diagnostic platform to enable earlier detection and more accurate differentiation of dementia subtypes. The project applies advanced multimodal approaches, combining biomarker profiling with analytical and imaging methods to improve diagnostic precision and accessibility.

As a Business Finland Research to Business (R2B) project, the focus is on applied research, validation, and commercialization readiness rather than basic scientific discovery. The project evaluates potential commercialization pathways, supports dissemination activities, and builds capabilities for future translation into clinical and market applications. By bridging research and application, the project aims to enhance clinical decision-making and contribute to more personalized and timely care for patients.

Principal Investigator:
Nsrein Ali, Nsrein.Ali@oulu.fi, +358503494212

Business Champions:
Sebastian Bisso Mifflin, Sebastian.BissoMifflin@oulu.fi

Julius Francis Gomes, Julius.FrancisGomes@oulu.fi, +358294487434